CordenPharma invests €900M in expanding peptide platform to meet GLP-1 drug demand 18-Jul-2024 By Clara Rodriguez Fernandez CordenPharma, a US-based contract development and manufacturing organization (CDMO), will be making a €900 million investment over the next three years into expanding its peptide technology platform at its US and Europe sites.
Jefferies Healthcare Conference: How CDMOs are embracing the obesity drugs craze 15-Nov-2023 By Isabel Cameron Weight loss drugs known as GLP-1s have caused a stir among patients and investors, with many CDMOs now looking to tap into the booming market.
A toxicologist’s perspective on good laboratory practice (GLP) standards versus non-GLP testing 19-Apr-2023 By WuXi AppTec's perspective on GLP versus non-GLP practices Since 1978, the US Food and Drug Administration has had in place the guidance for good laboratory practices (GLP) regulations.
Novo Nordisk gets nod for oral diabetes drug 23-Sep-2019 By Ben Hargreaves US FDA provides the first ever approval of an oral GLP-1 treatment to Novo Nordisk, for the treatment of type 2 diabetes.